A Randomised, Double Blind, Placebo-controlled, Multiple Dose, Phase 2b, 24 Week Trial Followed by an Open Label Extension of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Phase of Trial: Phase II
Latest Information Update: 18 Aug 2015
At a glance
- Drugs Fletikumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 10 Jun 2017 Biomarkers information updated
- 19 Nov 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
- 20 Aug 2014 Planned End Date changed from 1 Dec 2015 to 1 Nov 2014 as reported by ClinicalTrials.gov record.